These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27255405)

  • 1. Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.
    Parellada E; Bioque M
    CNS Drugs; 2016 Aug; 30(8):689-701. PubMed ID: 27255405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
    Biagi E; Capuzzi E; Colmegna F; Mascarini A; Brambilla G; Ornaghi A; Santambrogio J; Clerici M
    Adv Ther; 2017 May; 34(5):1036-1048. PubMed ID: 28382557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.
    Chue P; Emsley R
    CNS Drugs; 2007; 21(6):441-8. PubMed ID: 17521224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
    Stevens GL; Dawson G; Zummo J
    Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month paliperidone palmitate - a new treatment option for schizophrenia.
    Bernardo M; Bioque M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):899-904. PubMed ID: 27206330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care.
    Lauriello J; Perkins DO
    J Clin Psychiatry; 2019 Feb; 80(1):. PubMed ID: 30786179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical guideline recommendations for antipsychotic long-acting injections.
    Kane JM; Garcia-Ribera C
    Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking the role of long-acting atypical antipsychotics in the community setting.
    Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
    Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia--A 3-year follow-up.
    Liu CC; Shan JC; Chiang CL; Hsieh MH; Liu CM; Chien YL; Chen SC; Hwang TJ
    J Formos Med Assoc; 2015 Jun; 114(6):539-45. PubMed ID: 26062967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting patients for long-acting novel antipsychotic therapy.
    Lambert T
    Australas Psychiatry; 2006 Mar; 14(1):38-42. PubMed ID: 16630195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.